Many pharmaceutical companies listed strategic objectives for 2024 that included solving for health inequities, clearly positioned within pillars that focused on improving or increasing the value of their products. For one reason or another, many of those objectives were set aside as planning commenced in the new year, leaving this crushing challenge to our society unaddressed.
Tag Archive for: health equity
Excitement is mounting across the industry going into 2024 about data and digital innovations’ potential for improving engagement among consumers, patients, and caregivers. That excitement is evident in conversations with eight industry leaders who are embracing digital to advance personalization, support health equity, and reach patients on new channels.
We at Med Ad News don’t claim to know all the questions. So we challenged our contributors to come up with their own questions and answer them.
As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care, and pharma and biotech companies’ increased investment in “access,” but there are two trends that are at the top of the “what we’re watching” list for 2024.
The HBA has announced the 2024 Woman of the Year, Honorable Mentor, and STAR. Recognized for their outstanding contributions to healthcare and the advancement of women in the workplace, the honorees will be celebrated at HBA’s 34th annual Woman of the Year event on May 10 in New York City and remotely around the globe.
This is a critical time in the evolution of technology-driven innovation in the field of pharma and life sciences. In the same way that innovations such as the steam engine and electricity transformed our world, AI is set to be one of the defining innovations of our lifetime.
Part I: From patient access issues to significant cost cutting to the Inflation Reduction Act, there are a host of challenges that the industry is up against in 2024. Our experts weigh in.
Part II: Agencies are striving to make inclusion and representation a priority at their organizations as well as when working with clients.
Part V: Cost pressures, increasing value while improving health outcomes, and leveraging real-world evidence are top of mind.
The importance of diversity in clinical research has gained significant recognition, driven by its potential to reduce healthcare disparities, enhance patient outcomes, enrich medical education, and broaden research methodologies. However, consistent underrepresentation of racial and ethnic minorities in clinical trials poses a barrier to the generalizability of research findings.
